Tay-Sachs disease is diagnosed primarily through a blood test that measures the activity of a specific enzyme. When that enzyme, called hexosaminidase A (Hex A), falls below 20% of total hexosaminidase activity, the result is consistent with Tay-Sachs. Genetic testing can then confirm the diagnosis by identifying mutations in the HEXA gene. The diagnostic process looks different depending on whether the person is a symptomatic infant, an adult with unexplained neurological problems, or a healthy adult checking their carrier status before starting a family.
The Enzyme Blood Test
The cornerstone of Tay-Sachs diagnosis is an enzyme assay, a blood test that measures how much Hex A activity is present in white blood cells. Normally, Hex A makes up 63% to 75% of total hexosaminidase activity. In someone with Tay-Sachs, that number drops below 20%. The test is straightforward: a standard blood draw sent to a specialized lab, with results typically reported as a percentage of total enzyme activity.
This same test can also identify carriers, people who have one copy of the faulty gene but no symptoms. Carriers usually show Hex A levels below 58%. There’s also an indeterminate zone between 58% and 62%, where the result isn’t clear enough to classify someone as a carrier or non-carrier. People who fall in that range are referred for genetic (molecular) testing to get a definitive answer.
One important nuance: some people carry what’s called a “pseudodeficiency allele,” a genetic variant that lowers enzyme activity on lab tests but doesn’t actually cause disease. Molecular testing can distinguish these harmless variants from true disease-causing mutations, which matters enormously for family planning decisions.
Genetic Testing for Confirmation
Genetic testing analyzes the HEXA gene directly, looking for known mutations that cause Tay-Sachs. It serves two purposes: confirming a diagnosis when enzyme levels are abnormal, and clarifying ambiguous enzyme results. For people of Ashkenazi Jewish descent, where Tay-Sachs is more common, combined enzyme and DNA testing catches over 98% of carriers when all four grandparents share that heritage. In more ethnically diverse populations, the detection rate is still above 92%.
The enzyme assay has one major advantage over genetic testing alone: it works well regardless of ethnic background, because it measures actual enzyme function rather than looking for specific mutations that vary across populations. For this reason, many screening programs use the enzyme test first and follow up with genetic testing when needed.
How Infantile Tay-Sachs Is Recognized
In the classic infantile form, symptoms typically appear between 3 and 6 months of age, when a baby begins losing developmental milestones. An exaggerated startle response to loud sounds is often one of the earliest signs parents notice. During an eye exam, doctors look for a distinctive finding called a cherry-red spot on the retina, which appears in roughly 90% of affected infants. This spot forms because the nerve cells surrounding the central part of the retina become swollen with stored material, making the normal red center stand out in contrast.
While the cherry-red spot is a strong clinical clue, it isn’t unique to Tay-Sachs. It can appear in several other storage disorders. The enzyme blood test is what confirms the specific diagnosis.
Late-Onset Tay-Sachs in Adults
Not all Tay-Sachs presents in infancy. Late-onset Tay-Sachs (LOTS) can appear in the teens or adulthood, and it’s notoriously difficult to diagnose because the symptoms mimic other neurological conditions. People with LOTS may develop muscle weakness, coordination problems, tremors, slurred speech, or psychiatric symptoms like depression and psychosis, in various combinations that don’t immediately point to a single diagnosis.
The key to catching LOTS is measuring enzyme activity when the clinical picture is suspicious. Total hexosaminidase levels can appear completely normal in these patients, which is misleading. In one documented case, total hexosaminidase was 13.6 U/L, well within the normal reference range, but Hex A activity specifically was absent. This is why labs must measure Hex A as a distinct fraction, not just total enzyme levels. Genetic testing then confirms the diagnosis by identifying the specific mutations involved. In LOTS, patients are often compound heterozygous, meaning they carry two different HEXA mutations rather than two copies of the same one.
Distinguishing Tay-Sachs From Similar Conditions
Tay-Sachs belongs to a group of related disorders called GM2 gangliosidoses. The most important condition to differentiate it from is Sandhoff disease, which looks nearly identical clinically. The distinction comes down to enzyme patterns: Tay-Sachs shows a decrease in Hex A only, while Sandhoff disease shows decreased levels of both Hex A and Hex B. A third, rarer variant (called the AB variant) shows normal enzyme levels but a deficiency in a helper protein that the enzymes need to function. The enzyme assay reliably separates Tay-Sachs from Sandhoff, while the AB variant requires additional specialized testing.
Carrier Screening Before Pregnancy
For many people, the first encounter with Tay-Sachs testing happens not because of symptoms but because of family planning. Carrier screening is recommended for individuals of Ashkenazi Jewish, French-Canadian, or Cajun descent, populations where the carrier rate is significantly higher. Both partners need to be carriers for a pregnancy to be at risk, so testing both parents before or early in pregnancy gives families information to guide their decisions.
Screening typically starts with the enzyme assay. If results are positive or indeterminate, molecular testing follows. One practical consideration: pregnancy, oral contraceptives, and certain medical conditions can affect enzyme levels in blood serum, so labs often use white blood cells (leukocytes) rather than serum for more reliable results in women who are pregnant or on hormonal birth control.
Prenatal Diagnosis
When both parents are confirmed carriers, prenatal testing can determine whether the fetus is affected. Two procedures are available, differing mainly in timing. Chorionic villus sampling (CVS) can be performed between weeks 10 and 13 of pregnancy by taking a small tissue sample from the placenta. Amniocentesis, which collects a sample of amniotic fluid, happens later, around week 16. Both provide cells that can be tested for Hex A enzyme activity and HEXA gene mutations.
CVS offers the advantage of earlier results, giving families more time to process information and consider options. Amniocentesis is sometimes chosen when CVS isn’t available or when earlier results were inconclusive. Preimplantation genetic testing during IVF is also an option for carrier couples who want to screen embryos before pregnancy begins.
Why Tay-Sachs Is Not on Newborn Screening Panels
Despite the availability of a reliable enzyme test, Tay-Sachs is not included on standard newborn screening panels in the United States. Newborn screening programs focus on conditions where early detection changes outcomes through available treatments. Because there is currently no treatment that can halt or reverse the progression of infantile Tay-Sachs, the emphasis remains on carrier screening before conception and prenatal testing during pregnancy rather than newborn detection after birth.